Discovery and development of direct Xa inhibitors
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
Discovery and development of direct Xa inhibitors
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
has abstract
Four drugs from the class of d ...... as approved in the US in 2017.
@en
Wikipage page ID
51,714,214
page length (characters) of wiki page
Wikipage revision ID
998,909,313
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
comment
Four drugs from the class of d ...... as approved in the US in 2017.
@en
label
Discovery and development of direct Xa inhibitors
@en